Use of modulated MHC lactate formulation in the preparation of a medicament for promoting diseases associated with lactate levels in the body

By regulating MHC lactation agents and using p300 activators and SIRT1 inhibitors to modulate α-MHC-K1897 lactation, the problem of decreased myocardial contractility and fibrosis caused by hypertension has been solved, providing a new treatment method for heart failure, improving myocardial function and reducing fibrosis.

CN116808217BActive Publication Date: 2026-04-07THE FIRST HOSPITAL OF CHINA MEDICIAL UNIV
2 Cites 0 Cited by

Patent Information

Application Number
CN202310662298.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-06
Publication Date
2026-04-07
Estimated Expiration
2043-06-06

AI Technical Summary

Technical Problem

The pathogenesis of heart failure is not yet fully understood, especially the decline in myocardial contractility and fibrosis caused by hypertension. Existing treatments are unable to effectively regulate the lactation level of α-MHC-K1897, leading to the aggravation of heart failure.

Method used

By using p300 activators and SIRT1 inhibitors to regulate the lactation level of α-MHC-K1897, the lactation modification of Myh6-K1897 in the treatment of heart failure can be affected, providing a new therapeutic approach for heart failure.

Benefits of technology

It significantly improved myocardial function, reduced myocardial fibrosis and hypertrophy, enhanced the function of myocardial cells under stress injury, and provided a new treatment method for heart failure.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of an MHC lactation modifier in the preparation of drugs for diseases related to promoting the body's lactation level. Specifically, it relates to the application of an MHC lactation modifier in the preparation of drugs for diseases related to promoting the body's lactation level, and the application of an MHC lactation modifier in the preparation of drugs for heart failure. The heart failure is defined as heart failure caused by decreased α-MHC-K1897 lactation due to Ang II-induced vasoconstriction. The invention also relates to the application of the aforementioned MHC lactation modifier in the preparation of drugs for heart failure caused by Ang II-induced vasoconstriction in humans, mice, or dogs. This invention also discovers new uses for p300 activators and SIRT1 inhibitors. Experimental studies have shown that treatment with p300 activators and SIRT1 inhibitors can affect the level of Myh6-K1897 lactation in the treatment of heart failure. The modification of Myh6-K1897 lactation as a therapeutic target plays an important role in the treatment of heart failure, providing a new approach to the treatment of heart failure.
Need to check novelty before this filing date? Find Prior Art